Alterity Therapeutics Limited — Form 6-K Summary
Business Context and Reporting Period
Alterity Therapeutics Limited, an Australian development-stage enterprise, filed this Form 6-K for the month of September 2026. The company files annual reports on Form 20-F and is headquartered in Melbourne, Victoria, Australia.
Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes Versus Prior Period
The filing text does not provide financial or operating comparisons with a prior period. It submits Exhibit 99.1, titled “Date of AGM and Closing Date for Director Nominations,” but the exhibit’s substantive contents are not included in the provided filing text.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risks, contingencies, or unusual financial items are disclosed in the provided text.
The Form 6-K states that it is incorporated by reference into the company’s Form S-8 registration statements and Form F-3 registration statement. The report was signed by Chairman Julian Babarczy on September 25, 2026.
Important Facts to Verify
- Obtain and review Exhibit 99.1 to confirm the annual general meeting date and the closing date for director nominations.
- Confirm whether any separate September 2026 disclosures contain financial, clinical, financing, or corporate updates.
- Review the company’s latest Form 20-F and subsequent filings for cash runway, financing needs, development-stage risks, and liquidity information.
- Confirm the scope and effect of the registration statements incorporated by reference.